GlassScriptPhysician profile
Michael Enrico
NPI 1912960006
$36,660.46
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $4,422 · 2021: $11K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27,087.51 | 2019-2021 | |
| Organon LLC | $9,488.12 | 2021 | |
| Roche Diagnostics Corporation | $28.51 | 2019-2020 | |
| Therapeuticsmd, INC. | $24.68 | 2019-2020 | |
| Olympus America INC. | $17.24 | 2019 | |
| Astellas Pharma US INC | $14.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Enrico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.